Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial.

Hvistendahl MK, Naimi RM, Enevoldsen LH, Madsen JL, Fuglsang S, Jeppesen PB

JPEN. Journal of parenteral and enteral nutrition5 Feb 2020Cited by 38 (Europe PMC)

PMID32022286DOI10.1002/jpen.1767PepBankPUB-32022286

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with short bowel syndrome, glepaglutide increased time to 10% gastric emptying of solids by 27 minutes from baseline (95% CI 4-50).
In plain wordsIn patients with short bowel syndrome, glepaglutide increased time to 10% gastric emptying of solids from baseline.
Peptide
Glepaglutide
Outcome
IncreaseTime to 10% gastric emptying of solids
Study
n = 9
Comparator
Baseline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Measurements
Increase in time to 10% gastric emptying of solids
27 minutes
10-mg dose group, adjusted mean change from baseline
Source sentences
Summary
In the 10-mg dose group (n = 9), glepaglutide significantly increased time to 10% gastric emptying (GE) of solids by 27 (4-50) minutes (adjusted mean [95% CI]), time to 50%GE of fluids by 40 (1-80) minutes, and time to 10% small bowel-emptying of solids by 21 (1-41) minutes.
2 context sentences(design, population, supporting numbers)
Summary · context
In this single-center, double-blind, dose-finding, phase 2 trial, patients with SBS were randomly assigned to 3 treatments (0.1, 1, and 10 mg) in a 2-period crossover design.
Summary · context
Each treatment period included 3 weeks of daily, subcutaneous glepaglutide injections separated by a washout period of 4-8 weeks.
Report a problemFND-3202228601
02HumanRandomized controlled trialEfficacy outcome
In patients with short bowel syndrome, glepaglutide increased time to 50% gastric emptying of fluids by 40 minutes from baseline (95% CI 1-80).
In plain wordsIn patients with short bowel syndrome, glepaglutide increased time to 50% gastric emptying of fluids from baseline.
Peptide
Glepaglutide
Outcome
IncreaseTime to 50% gastric emptying of fluids
Study
n = 9
Comparator
Baseline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Measurements
Increase in time to 50% gastric emptying of fluids
40 minutes
10-mg dose group, adjusted mean change from baseline
Source sentences
Summary
In the 10-mg dose group (n = 9), glepaglutide significantly increased time to 10% gastric emptying (GE) of solids by 27 (4-50) minutes (adjusted mean [95% CI]), time to 50%GE of fluids by 40 (1-80) minutes, and time to 10% small bowel-emptying of solids by 21 (1-41) minutes.
2 context sentences(design, population, supporting numbers)
Summary · context
In this single-center, double-blind, dose-finding, phase 2 trial, patients with SBS were randomly assigned to 3 treatments (0.1, 1, and 10 mg) in a 2-period crossover design.
Summary · context
Each treatment period included 3 weeks of daily, subcutaneous glepaglutide injections separated by a washout period of 4-8 weeks.
Report a problemFND-3202228602
03HumanRandomized controlled trialEfficacy outcome
In patients with short bowel syndrome, glepaglutide increased time to 10% small bowel emptying of solids by 21 minutes from baseline (95% CI 1-41).
In plain wordsIn patients with short bowel syndrome, glepaglutide increased time to 10% small bowel emptying of solids from baseline.
Peptide
Glepaglutide
Outcome
IncreaseTime to 10% small bowel emptying of solids
Study
n = 9
Comparator
Baseline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Measurements
Increase in time to 10% small bowel emptying of solids
21 minutes
10-mg dose group, adjusted mean change from baseline
Source sentences
Summary
In the 10-mg dose group (n = 9), glepaglutide significantly increased time to 10% gastric emptying (GE) of solids by 27 (4-50) minutes (adjusted mean [95% CI]), time to 50%GE of fluids by 40 (1-80) minutes, and time to 10% small bowel-emptying of solids by 21 (1-41) minutes.
2 context sentences(design, population, supporting numbers)
Summary · context
In this single-center, double-blind, dose-finding, phase 2 trial, patients with SBS were randomly assigned to 3 treatments (0.1, 1, and 10 mg) in a 2-period crossover design.
Summary · context
Each treatment period included 3 weeks of daily, subcutaneous glepaglutide injections separated by a washout period of 4-8 weeks.
Report a problemFND-3202228603
04HumanRandomized controlled trialEfficacy outcome
In patients with short bowel syndrome, glepaglutide significantly increased maximum paracetamol concentration from baseline.
In plain wordsIn patients with short bowel syndrome, glepaglutide significantly increased maximum paracetamol concentration from baseline.
Peptide
Glepaglutide
Outcome
IncreaseMaximum paracetamol concentration
Study
n = 9
Comparator
Baseline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Source sentences
Summary
The maximum paracetamol concentration significantly increased in the 10-mg dose group; however, the area under the curve remained the same.
2 context sentences(design, population, supporting numbers)
Summary · context
In this single-center, double-blind, dose-finding, phase 2 trial, patients with SBS were randomly assigned to 3 treatments (0.1, 1, and 10 mg) in a 2-period crossover design.
Summary · context
Each treatment period included 3 weeks of daily, subcutaneous glepaglutide injections separated by a washout period of 4-8 weeks.
Report a problemFND-3202228605
05HumanRandomized controlled trialEfficacy outcome
In patients with short bowel syndrome, paracetamol area under the curve remained unchanged from baseline with glepaglutide.
In plain wordsIn patients with short bowel syndrome, paracetamol area under the curve remained unchanged from baseline with glepaglutide.
Peptide
Glepaglutide
Outcome
No significant changeParacetamol area under the curve
Study
n = 9
Comparator
Baseline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Source sentences
Summary
The maximum paracetamol concentration significantly increased in the 10-mg dose group; however, the area under the curve remained the same.
2 context sentences(design, population, supporting numbers)
Summary · context
In this single-center, double-blind, dose-finding, phase 2 trial, patients with SBS were randomly assigned to 3 treatments (0.1, 1, and 10 mg) in a 2-period crossover design.
Summary · context
Each treatment period included 3 weeks of daily, subcutaneous glepaglutide injections separated by a washout period of 4-8 weeks.
Report a problemFND-3202228606
06HumanRandomized controlled trialEfficacy outcome
In patients with short bowel syndrome, wireless motility capsule transit did not significantly change from baseline in any glepaglutide dose group.
In plain wordsIn patients with short bowel syndrome, capsule transit did not significantly change from baseline in any glepaglutide dose group.
Peptide
Glepaglutide
Outcome
No significant changeWireless motility capsule transit
Study
n: not reported in source
Comparator
Baseline
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
0.1, 1, and 10 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Source sentences
Summary
The WMC transit did not significantly change in any of the dose groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this single-center, double-blind, dose-finding, phase 2 trial, patients with SBS were randomly assigned to 3 treatments (0.1, 1, and 10 mg) in a 2-period crossover design.
Summary · context
Each treatment period included 3 weeks of daily, subcutaneous glepaglutide injections separated by a washout period of 4-8 weeks.
Report a problemFND-3202228604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.